Lysine (lys) (acetylated) Antikörper (Biotin)

Produktnummer ABIN361691

Produktdetails

Target: Lysine (lys)

Bindungsspezifität: acetylated

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Biotin

Applikation: Immunocytochemistry (ICC), Immunofluorescence (IF), Immunoprecipitation (IP), ELISA, Western Blotting (WB)

Spezifität: Detects proteins containing acetylated lysine residues. No reaction to non-acetylated proteins.

Aufreinigung: Protein A Purified

Immunogen: Acetylated KLH Conjugated

Anwendungsinformationen

Applikationshinweise:

• WB (1:250)
• ICC/IF (1:100)
• optimal dilutions for assays should be determined by the user.

Kommentare:

A 1/250 dilution of SPC-156 was sufficient to detect the acetylated histone from TSA treated mouse spleen cell in western blot analysis.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.25 mg/mL

Buffer: PBS, 50 % glycerol, 0.09 % sodium azide, Storage buffer may change when conjugated

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Conjugated antibodies should be stored at 4°C

Antigendetails

Target: Lysine (lys)

Andere Bezeichnung: Lysine

Substanzklasse: Amino Acid

Hintergrund: Post-translational modifications of proteins play critical roles in the regulation and function of many known biological processes. Proteins can be post-translationally modified in many different ways, and a common post-transcriptional modification of Lysine involves acetylation (1). The conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) contain lysines that are acetylated by histone acetyltransferases (HATs) and deacetylated by histone deacetylases (HDACs) (2). Protein posttranslational reversible lysine Nε-acetylation and deacetylation have been recognized as an emerging intracellular signaling mechanism that plays critical roles in regulating gene transcription, cell-cycle progression, apoptosis, DNA repair, and cytoskeletal organization (3). The regulation of protein acetylation status is impaired in the pathologies of cancer and polyglutamine diseases (4), and HDACs have become promising targets for anti-cancer drugs currently in development (5).